Bionano Genomics, Inc. (NASDAQ: BNGO) Stock Competitors & Peer Comparison
See BNGO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BNGO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BNGO | $1.33 | +9.02% | 15.3M | -0.30 | -$4.37 | N/A |
| ISRG | $377.94 | +2.38% | 133.5B | 39.29 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| BDX | $182.91 | +2.85% | 50.4B | 14.07 | $13.00 | +2.25% |
| RMD | $222.99 | +2.16% | 32.3B | 20.70 | $10.77 | +1.13% |
| MDLN | $32.59 | +0.18% | 27.6B | 23.88 | $1.36 | N/A |
| WST | $355.20 | +2.59% | 25B | 41.78 | $8.50 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $89.82 | +2.71% | 15.6B | 12.65 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
BNGO vs ISRG Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ISRG has a market cap of 133.5B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ISRG trades at $377.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ISRG's P/E ratio is 39.29. In terms of profitability, BNGO's ROE is -0.79%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, BNGO is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BNGO vs BDXA Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BNGO's ROE is -0.79%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, BNGO is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
BNGO vs BDX Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, BDX has a market cap of 50.4B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while BDX trades at $182.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas BDX's P/E ratio is 14.07. In terms of profitability, BNGO's ROE is -0.79%, compared to BDX's ROE of +0.04%. Regarding short-term risk, BNGO is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
BNGO vs RMD Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, RMD has a market cap of 32.3B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while RMD trades at $222.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas RMD's P/E ratio is 20.70. In terms of profitability, BNGO's ROE is -0.79%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BNGO is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
BNGO vs MDLN Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, MDLN has a market cap of 27.6B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while MDLN trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas MDLN's P/E ratio is 23.88. In terms of profitability, BNGO's ROE is -0.79%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BNGO is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BNGO vs WST Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, WST has a market cap of 25B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while WST trades at $355.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas WST's P/E ratio is 41.78. In terms of profitability, BNGO's ROE is -0.79%, compared to WST's ROE of +0.19%. Regarding short-term risk, BNGO is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BNGO vs HOLX Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BNGO's ROE is -0.79%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BNGO is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
BNGO vs SOLV Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while SOLV trades at $89.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas SOLV's P/E ratio is 12.65. In terms of profitability, BNGO's ROE is -0.79%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, BNGO is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BNGO vs BDXB Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BNGO's ROE is -0.79%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BNGO is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BNGO vs BAX Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while BAX trades at $23.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas BAX's P/E ratio is 11.47. In terms of profitability, BNGO's ROE is -0.79%, compared to BAX's ROE of -0.17%. Regarding short-term risk, BNGO is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BNGO vs COO Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, COO has a market cap of 10.6B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while COO trades at $54.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas COO's P/E ratio is 11.88. In terms of profitability, BNGO's ROE is -0.79%, compared to COO's ROE of +0.07%. Regarding short-term risk, BNGO is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
BNGO vs AVTR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, AVTR has a market cap of 10.2B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while AVTR trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas AVTR's P/E ratio is 17.82. In terms of profitability, BNGO's ROE is -0.79%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BNGO is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BNGO vs RGEN Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, RGEN has a market cap of 9.5B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while RGEN trades at $168.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas RGEN's P/E ratio is 93.33. In terms of profitability, BNGO's ROE is -0.79%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BNGO is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
BNGO vs ATR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ATR trades at $124.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ATR's P/E ratio is 21.84. In terms of profitability, BNGO's ROE is -0.79%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BNGO is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BNGO vs BLCO Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, BLCO has a market cap of 6.3B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while BLCO trades at $17.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas BLCO's P/E ratio is 27.06. In terms of profitability, BNGO's ROE is -0.79%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BNGO is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BNGO vs STVN Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while STVN trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas STVN's P/E ratio is 32.22. In terms of profitability, BNGO's ROE is -0.79%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BNGO is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
BNGO vs TFX Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while TFX trades at $130.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas TFX's P/E ratio is 14.87. In terms of profitability, BNGO's ROE is -0.79%, compared to TFX's ROE of -0.32%. Regarding short-term risk, BNGO is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BNGO vs MMSI Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while MMSI trades at $87.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas MMSI's P/E ratio is 22.26. In terms of profitability, BNGO's ROE is -0.79%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BNGO is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
BNGO vs NVST Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, NVST has a market cap of 4.2B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while NVST trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas NVST's P/E ratio is 17.54. In terms of profitability, BNGO's ROE is -0.79%, compared to NVST's ROE of +0.04%. Regarding short-term risk, BNGO is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BNGO vs ICUI Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ICUI trades at $157.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ICUI's P/E ratio is 19.68. In terms of profitability, BNGO's ROE is -0.79%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, BNGO is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BNGO vs PLSE Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while PLSE trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas PLSE's P/E ratio is -45.94. In terms of profitability, BNGO's ROE is -0.79%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, BNGO is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BNGO vs ATRC Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ATRC trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ATRC's P/E ratio is 1732.61. In terms of profitability, BNGO's ROE is -0.79%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BNGO is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BNGO vs XRAY Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while XRAY trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas XRAY's P/E ratio is 7.26. In terms of profitability, BNGO's ROE is -0.79%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, BNGO is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BNGO vs LMAT Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while LMAT trades at $80.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas LMAT's P/E ratio is 29.69. In terms of profitability, BNGO's ROE is -0.79%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BNGO is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BNGO vs BLFS Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while BLFS trades at $35.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas BLFS's P/E ratio is -167.64. In terms of profitability, BNGO's ROE is -0.79%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, BNGO is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BNGO vs AZTA Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while AZTA trades at $32.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas AZTA's P/E ratio is 76.29. In terms of profitability, BNGO's ROE is -0.79%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BNGO is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BNGO vs KMTS Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, KMTS has a market cap of 1.4B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while KMTS trades at $24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas KMTS's P/E ratio is -10.19. In terms of profitability, BNGO's ROE is -0.79%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BNGO is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BNGO vs STAA Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while STAA trades at $23.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas STAA's P/E ratio is 40.47. In terms of profitability, BNGO's ROE is -0.79%, compared to STAA's ROE of +0.01%. Regarding short-term risk, BNGO is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
BNGO vs ATRI Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BNGO's ROE is -0.79%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BNGO is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BNGO vs ANGO Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ANGO has a market cap of 641.1M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ANGO trades at $15.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ANGO's P/E ratio is -39.77. In terms of profitability, BNGO's ROE is -0.79%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BNGO is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BNGO vs SMTI Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, SMTI has a market cap of 321.6M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while SMTI trades at $34.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas SMTI's P/E ratio is -583.00. In terms of profitability, BNGO's ROE is -0.79%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BNGO is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
BNGO vs EMBC Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, EMBC has a market cap of 310.9M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while EMBC trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas EMBC's P/E ratio is 2.02. In terms of profitability, BNGO's ROE is -0.79%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, BNGO is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BNGO vs NNNN Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, NNNN has a market cap of 268.2M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while NNNN trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas NNNN's P/E ratio is 88.29. In terms of profitability, BNGO's ROE is -0.79%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BNGO is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BNGO vs OSUR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, OSUR has a market cap of 232M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while OSUR trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas OSUR's P/E ratio is -4.88. In terms of profitability, BNGO's ROE is -0.79%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BNGO is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BNGO vs UTMD Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, UTMD has a market cap of 225M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while UTMD trades at $70.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas UTMD's P/E ratio is 20.91. In terms of profitability, BNGO's ROE is -0.79%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BNGO is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BNGO vs PDEX Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, PDEX has a market cap of 212.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while PDEX trades at $66.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas PDEX's P/E ratio is 16.12. In terms of profitability, BNGO's ROE is -0.79%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, BNGO is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BNGO vs KRMD Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, KRMD has a market cap of 144.2M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while KRMD trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas KRMD's P/E ratio is -78.50. In terms of profitability, BNGO's ROE is -0.79%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BNGO is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
BNGO vs STXS Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, STXS has a market cap of 130.7M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while STXS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas STXS's P/E ratio is -7.85. In terms of profitability, BNGO's ROE is -0.79%, compared to STXS's ROE of -1.33%. Regarding short-term risk, BNGO is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
BNGO vs DXR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, DXR has a market cap of 65.8M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while DXR trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas DXR's P/E ratio is 9.17. In terms of profitability, BNGO's ROE is -0.79%, compared to DXR's ROE of +0.13%. Regarding short-term risk, BNGO is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BNGO vs AKYA Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BNGO's ROE is -0.79%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BNGO is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
BNGO vs STSS Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas STSS's P/E ratio is -0.02. In terms of profitability, BNGO's ROE is -0.79%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BNGO is more volatile compared to STSS. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BNGO vs OMIC Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BNGO's ROE is -0.79%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BNGO is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BNGO vs IGAP Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BNGO's ROE is -0.79%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, BNGO is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BNGO vs NEPH Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, NEPH has a market cap of 48.1M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while NEPH trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas NEPH's P/E ratio is 73.83. In terms of profitability, BNGO's ROE is -0.79%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, BNGO is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BNGO vs POCI Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, POCI has a market cap of 47.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while POCI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas POCI's P/E ratio is -6.89. In terms of profitability, BNGO's ROE is -0.79%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BNGO is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BNGO vs MLSS Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, MLSS has a market cap of 37.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while MLSS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas MLSS's P/E ratio is -8.48. In terms of profitability, BNGO's ROE is -0.79%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BNGO is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BNGO vs HBIO Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, HBIO has a market cap of 36.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while HBIO trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas HBIO's P/E ratio is -22.47. In terms of profitability, BNGO's ROE is -0.79%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BNGO is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BNGO vs SDC Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas SDC's P/E ratio is -0.03. In terms of profitability, BNGO's ROE is -0.79%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BNGO is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
BNGO vs IVC Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas IVC's P/E ratio is -0.79. In terms of profitability, BNGO's ROE is -0.79%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BNGO is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BNGO vs RVP Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas RVP's P/E ratio is -5.72. In terms of profitability, BNGO's ROE is -0.79%, compared to RVP's ROE of -0.05%. Regarding short-term risk, BNGO is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BNGO vs ZJYL Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ZJYL has a market cap of 15M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ZJYL trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ZJYL's P/E ratio is 13.13. In terms of profitability, BNGO's ROE is -0.79%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BNGO is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BNGO vs RGNT Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, RGNT has a market cap of 13.3M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while RGNT trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BNGO's ROE is -0.79%, compared to RGNT's ROE of N/A. Regarding short-term risk, BNGO is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
BNGO vs CUPR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, CUPR has a market cap of 8.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while CUPR trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas CUPR's P/E ratio is -2.29. In terms of profitability, BNGO's ROE is -0.79%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, BNGO is more volatile compared to CUPR. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
BNGO vs FEMY Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, FEMY has a market cap of 7.9M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while FEMY trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas FEMY's P/E ratio is -0.58. In terms of profitability, BNGO's ROE is -0.79%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, BNGO is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
BNGO vs LUCY Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while LUCY trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas LUCY's P/E ratio is -0.49. In terms of profitability, BNGO's ROE is -0.79%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BNGO is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BNGO vs NSTG Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BNGO's ROE is -0.79%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BNGO is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BNGO vs POAI Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas POAI's P/E ratio is -0.03. In terms of profitability, BNGO's ROE is -0.79%, compared to POAI's ROE of -21.19%. Regarding short-term risk, BNGO is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BNGO vs MHUA Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BNGO's ROE is -0.79%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BNGO is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BNGO vs NXGL Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while NXGL trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas NXGL's P/E ratio is -0.40. In terms of profitability, BNGO's ROE is -0.79%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, BNGO is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BNGO vs GMVD Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BNGO's ROE is -0.79%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BNGO is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BNGO vs GMVDW Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BNGO's ROE is -0.79%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BNGO is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BNGO vs AVGR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BNGO's ROE is -0.79%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BNGO is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BNGO vs NXGLW Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, NXGLW has a market cap of 1.1M. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, BNGO's ROE is -0.79%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, BNGO is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BNGO vs LUCYW Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BNGO's ROE is -0.79%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BNGO is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BNGO.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
BNGO vs APR Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas APR's P/E ratio is 22.59. In terms of profitability, BNGO's ROE is -0.79%, compared to APR's ROE of +9.81%. Regarding short-term risk, BNGO is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
BNGO vs IIN Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas IIN's P/E ratio is 226.45. In terms of profitability, BNGO's ROE is -0.79%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BNGO is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
BNGO vs ALOG Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BNGO's ROE is -0.79%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BNGO is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
BNGO vs IVTY Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BNGO's ROE is -0.79%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BNGO is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BNGO vs ATRS Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BNGO's ROE is -0.79%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BNGO is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BNGO vs HRC Comparison September 2026
Bionano Genomics, Inc. (NASDAQ: BNGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNGO stands at 15.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, BNGO is priced at $1.33 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNGO currently has a P/E ratio of -0.30, whereas HRC's P/E ratio is 41.92. In terms of profitability, BNGO's ROE is -0.79%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BNGO is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BNGO.Check HRC's competition here